Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment

被引:30
|
作者
van Geffen, Erica C. G. [1 ]
van Hulten, Rolf [1 ]
Bouvy, Marcel L. [2 ]
Egberts, Antoine C. G. [1 ]
Heerdink, Eibert R. [1 ]
机构
[1] Univ Utrecht, Fac Sci, Inst Pharmaceut Sci, Div Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] SIR Inst Pharm Practice & Policy, Leiden, Netherlands
关键词
adverse effects; nonadherence; selective serotonin-reuptake inhibitors;
D O I
10.1345/aph.1K516
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Studies have shown that up to 38% of patients who start treat ment with antidepressants fill only a single prescription at the pharmacy, I apparently not accepting treatment. OBJECTIVE: To determine characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor (SSRI) treatment. METHODS: A retrospective, study was conducted in 37 community pharmacies in the Netherlands; patients who presented a prescription from a general practitioner (GP) for a newly started SSRI treatment were selected. Nonaccepters were defined as patients who filled only one SSRI prescription; patients who received at least 3 fills of an SSRI prescription were defined as accepters. Patient characteristics were obtained from automated dispensing records and from questionnaires. Areas of evaluation included sociodemographics, disease, and treatment. Nonaccepters were asked their reasons for not filling second prescriptions. RESULTS: Of the patients who started SSRI treatment, 22.0% were nonaccepters, filling only a single prescription. Fifty-seven nonaccepters and 128 accepters were included in our analysis. Nonacceptance was more common among patients with a low level of education (OR 2.6; 95% CI 1.1 to 5.9) and in patients who reported nonspecific symptoms like fatigue, stress, and restlessness as the reason for SSRI use (OR 2.7; 95% CI 1.4 to 5.5). Of the nonaccepters, 29.8% (n = 17) did not start SSRI use, and 70.2% (n = 40) discontinued SSRI use within 2 weeks. Fear of adverse effects and the actual occurrence of adverse effects were main reasons for not accepting SSRI treatment. Of the nonaccepters, 55.0% discontinued treatment without informing their GPs. CONCLUSIONS: Acceptance of SSRI treatment is a decisive moment in a patient's adherence to treatment initiated by his or her GP and deserves more attention; GPs and pharmacists should address treatment issues, especially in groups at risk for nonacceptance.
引用
收藏
页码:218 / 225
页数:8
相关论文
共 50 条
  • [41] Selective serotonin-reuptake inhibitors and suicidal ideation and behavior in children
    Caballero, J
    Nahata, MC
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (08) : 864 - 867
  • [42] Selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitors and epidemiological characteristics associated with prenatal diagnosis of congenital heart disease
    Melov, Sarah J.
    Shetty, Prayatna Singh
    Pasupathy, Dharmintra
    Kirby, Adrienne
    Sholler, Gary F.
    Winlaw, David S.
    Alahakoon, Thushari, I
    PRENATAL DIAGNOSIS, 2021, 41 (01) : 35 - 42
  • [43] Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy
    Pae, Chi-Un
    Serretti, Alessandro
    Mandelli, Laura
    De Ronchi, Diana
    Patkar, Ashwin A.
    Jun, Tae-Youn
    Kim, Jung-Jin
    Lee, Chang-Uk
    Lee, Soo-Jung
    Lee, Chul
    Paik, In-Ho
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (01): : 69 - 75
  • [44] Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation
    Levent Ozcan
    Emre Can Polat
    Alper Otunctemur
    Emin Ozbek
    International Urology and Nephrology, 2015, 47 : 283 - 287
  • [45] Depressing observations on the use of selective serotonin-reuptake inhibitors during pregnancy
    Mills, JL
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06): : 636 - 638
  • [46] Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review
    Dimmock, PW
    Wyatt, KM
    Jones, PW
    O'Brien, PMS
    LANCET, 2000, 356 (9236): : 1131 - 1136
  • [47] Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation
    Ozcan, Levent
    Polat, Emre Can
    Otunctemur, Alper
    Ozbek, Emin
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2015, 47 (02) : 283 - 287
  • [48] Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn
    Chambers, CD
    Hernandez-Diaz, S
    Van Marter, LJ
    Werler, MM
    Louik, C
    Jones, KL
    Mitchell, AA
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06): : 579 - 587
  • [49] Use of Selective Serotonin-Reuptake Inhibitors during Pregnancy and the Risk of Clubfoot
    Yazdy, Mahsa M.
    Mitchell, Allen M.
    Louik, Carol
    Werler, Martha M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 376 - 376
  • [50] Use of the selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania
    Stein, DJ
    Bouwer, C
    Maud, CM
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1997, 247 (04) : 234 - 236